BARKER SAM L 4

What Happened

• Sam L. Barker, a director of Lexicon Pharmaceuticals (LXRX), reported conversion/exercise of a derivative on 2026-06-03 that resulted in the acquisition of 89,312 common shares at $0.00 and a simultaneous disposition of the derivative instrument for 89,312 units (transaction code M). No cash was paid or received in the reported entries.

Key Details

• Transaction date: 2026-06-03; Filing date: 2026-06-04 (timely).
• Reported amounts: 89,312 shares acquired @ $0.00; 89,312 derivative units disposed @ $0.00.
• Shares owned following the transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — the RSU vests 100% on the first anniversary of the grant; F2 — each RSU represents a contingent right to one share of common stock.
• This was not an open-market purchase or sale of stock (no proceeds or market sale reported).

Context

• The transaction appears to be the vesting/settlement of restricted stock units (RSUs) into common shares rather than a market buy or sell. For retail investors, such conversions are routine compensation/vesting events and do not necessarily signal a bullish or bearish view by the insider.